PEOPLE ON THE MOVE
Nordic Nanovector
Norwegian haematology and oncology drugmaker Nordic Nanovector has reshuffled its scientific advisory board.
CEO Luigi Costa said he was “delighted” at the new talent joining the company.
“I am confident that [the board’s] advice and guidance will prove invaluable as the company advances its development of Betalutin as a novel treatment for non-Hodgkin lymphoma and of its pipeline in the coming years.”
The SAB will be chaired by Timothy Illidge, Professor of Targeted Therapy and Oncology, University of Manchester, andPierluigi Zinzani, Associate Professor of Haematology at the University of Bologna.
The board also includes Arne Kolstad, of Oslo University Hospital Radiumhospitalet, Dolores Caballero of the University Hospital, Salamanca, Stephen Schuster of the University of Pennsylvania School of Medicine, Armando Lopez-Guillermo, Barcelona, Francesco D’Amore Aarhus University Hospital, Mark Kaminski, University of Michigan, Wojciech Jurczak, Jagiellonian University, Cracow, Lorenz Trumper, University Medical Center Göttingen, and Franck Morschhauser of the Centre Hospitalier Universitaire de Lille.
